EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Chimeric MHC class I– and II–restricted non-self epitopes broaden antitumor T cell reactions

Rongsheng Zhang, Rong Ma, Merrin M.L. Leong, Ian R. Watson, Kei Iida, Tomonori Yaguchi, Fumihiko Matsuda, Tasuku Honjo, Kenji Chamoto

Journal of Experimental Medicine · 2026-02-02 · 223 (2)

DOI: 10.1084/jem.20250025 ↗
AbstractBibliografische Angaben

Abstract

The mechanism by which one non-self antigen augments T cell immune responses to another remains unclear. We found that these expanded immune responses could derive from chimeric non-self peptides. These peptides, which we termed complete T cell antigens (CTAs), must be expressed intracellularly as single-chain chimeras containing both MHC class I– and II–restricted epitopes. CTAs, even unrelated to tumor antigens, when administered as live cell adjuvants or in cDNA-transfected muscle, increased T cell reactivity against tumor neoantigens. Mechanistically, CTA treatment altered dendritic cell phenotype in a CD4+ T cell–dependent manner, suppressing CD8+ T cell exhaustion and generating self-renewing CD8+ T cells in tumors. Cancers predicted to have long non-self peptides resulting from frameshift mutations, which frequently contain CTAs, were associated with a better prognosis or benefit from PD-1 blockade therapy in mouse models and cancer patients. These findings indicate that a subset of cancer cells expressing CTAs is sufficient to evoke overall antitumor immunity by broadening T cell responses to other neoantigens.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →